KAPANYSEPharmaceutical PreparationsFiscal year ends December 31
Kairos Pharma, LTD.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$0.57−0.03 (-5.19%)
Close on Oct 19, 2026
- Market cap
- $12.21M
- P/E (TTM)
- –
- Dividend yield
- –
Kairos Pharma statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Kairos Pharma | Industry median |
|---|---|---|
| Market Cap | $13.51M | $166.30M |
| Enterprise Value | $10.88M | $88.19M |
| PB Ratio | 3.22 | 2.03 |
| P/TBV Ratio | 3.38 | 2.29 |
Income (trailing twelve months)
| Measure | Kairos Pharma | Industry median |
|---|---|---|
| Operating Income | -$5.96M | -$21.40M |
| Net Income | -$5.81M | -$22.46M |
| EBITDA | -$5.96M | -$16.91M |
| EPS (Diluted) | -$0.28 | -$0.83 |
Returns
| Measure | Kairos Pharma | Industry median |
|---|---|---|
| Return on Equity (ROE) | -114.0% | -53.2% |
| Return on Assets (ROA) | -104.3% | -40.9% |
| Return on Invested Capital (ROIC) | -207.9% | -32.4% |
| Return on Capital Employed (ROCE) | -142.1% | -38.1% |
Balance sheet
| Measure | Kairos Pharma | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $2.63M | $61.43M |
| Net Cash (Debt) | $2.63M | $15.35M |
| Net Cash Per Share | $0.11 | $0.66 |
| Equity (Book Value) | $4.19M | $49.09M |
| Book Value Per Share | $0.18 | $1.37 |
| Tangible Book Value | $4.00M | $23.52M |
| Working Capital | $2.91M | $76.81M |
Financial position
| Measure | Kairos Pharma | Industry median |
|---|---|---|
| Current Ratio | 11.98 | 3.34 |
| Quick Ratio | 9.91 | 2.44 |
Cash flow (trailing twelve months)
| Measure | Kairos Pharma | Industry median |
|---|---|---|
| Operating Cash Flow | -$3.97M | -$12.35M |
Efficiency
| Measure | Kairos Pharma | Industry median |
|---|---|---|
| Profits Per Employee | -$5.81M | -$703.34K |
| Employee Count | 1 | 74 |
Dividends and yields
| Measure | Kairos Pharma | Industry median |
|---|---|---|
| Earnings Yield | -43.0% | -23.3% |
Shares
| Measure | Kairos Pharma | Industry median |
|---|---|---|
| Shares Outstanding | 23,697,700 | 58,127,000 |
| Shares Change (YoY) | 45.5% | 10.9% |
| Shares Change (QoQ) | 0.06% | 0.54% |
| Float | 16,095,000 | 49,136,700 |
| Shares Held by Insiders | 32.1% | 11.6% |
Scores
| Measure | Kairos Pharma | Industry median |
|---|---|---|
| Altman Z-Score | 21.52 | -0.22 |
| Piotroski F-Score | 3 | 4 |
Calculated by StockData from Kairos Pharma's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.